April 15, 2021 5:29pm

As all-time and intraday highs govern markets to which I say bye as the laws of gravity could come as a “force”

Pre-open indication performance: 4 HITs and 2 Miss

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing! 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

 


The Dow closed UP +305.10 points (+0.90%); the S&P closed UP +45.76 points (+1.11%) while the Nasdaq closed UP +180.92 points (+1.31%)

 

Henry’omics:

Indexes climbed to record levels on Thursday after key companies reported strong earnings and fresh economic data pointed to a rebound in consumer spending and the jobs market.

  • Plunging Treasury yields despite hot economic data fueled Thursday's market rally. The 10-year Treasury yield plunged 11 basis points to 1.53%, the lowest in several weeks.
  • Despite retail sales and jobless claims that were much better than expected; other reports showed strong growth.

 

Data Docket: Retail sales surged 9.8% in March as additional stimulus sent consumer spending soaring. That number topped the estimate of a 6.1% gain.

  • A separate report showed that first-time filings for unemployment insurance dropped to the lowest level since March 2020. The Labor Department reported 576,000 new jobless claims for the week ended April 10. Economists expected a total of 710,000.

 

RegMed Investors’ (RMi) pre-open: “fairly valued or subject to electronic trading selling any new highs. Retail and even institutional investors have lost any control of share pricing momentum.”https://www.regmedinvestors.com/articles/11867

 

Pre-open indication results:  4 HITs <SELL into Strength: Fate Therapeutics (FATE -$0.33), Regenxbio (RGNX +$0.53), CRISPR Therapeutics (CRSP +$0.74), Vericel (VCEL +$0.92)> and 2 MISS < Homology Medicine (FIXX -$0.19), Biostage (BSTG +$0.16 to $1.33 with 224 shares traded),

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Thursday opened positive at 22/9, 3 flats and 1 acquired, stayed positive at the mid-day to 18/16 and 1 acquired, closing positive at 18/16 and 1 acquired;

There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

  • Ultragenyx (RARE), Alnylam Pharmaceuticals (ALNY), Chinook Therapeutics (KDNY), CRISPR Therapeutics (CRSP), Vericel (VCEL) to name 5 of the 18 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), Intellia therapeutics (NTLA), Ionis Pharmaceuticals (IONS), Editas Medicine (EDIT), Fate Therapeutics (FATE) to name 5 of the 16 declining of the 35 covered

 

Key metrics:

  • Sector volume had LOW with 0 of the 18-upside having higher than the 3-month average volume with the volume of 1 of 16 downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 18-upside were +0.33% (BLFS) to +13.68% (BSTG) while the 16-downside ranges from -0.22% (SAGE) to -8.81% (BCLI);

 

Thursday’s (10 of 18) incline

  • Ultragenyx (RARE +$1.61 after Wednesday’s +$1.38, Tuesday’s +$6.06 and Monday’s -$2.95);
  • Chinook Therapeutics (KDNY+$1.44 after Wednesday’s -$0.11);
  • Vericel (VCEL +$0.92);
  • CRISPR Therapeutics (CRSP +$0.74 after Wednesday’s +$2.23, Tuesday’s +$6.49 and Monday’s -$1.35);
  • Alnylam Pharmaceuticals (ALNY +$0.71 after Wednesday’s +$2.08, Tuesday’s +$1.20 and Monday’s -$3.20);
  • uniQure NV (QURE +$0.59);
  • Precigen (PGEN +$0.55);
  • Regenxbio (RGNX +$0.53 after Wednesday’s +$0.68, Tuesday’s +$0.91 and Monday’s -$1.42);
  • Mesoblast (MESO +$0.30);
  • Adverum Biotechnologies (ADVM +$0.23);

Thursday’s (10 of 16) decliners:

  • ReNeuron (RENE.L -$8.00 after Wednesday’s +$1.50, Tuesday’s +$2.00 and Monday’s +$4.50);
  • Intellia Therapeutics (NTLA -$1.58 after Wednesday’s +$5.56, Tuesday’s +$2.38 and Monday’s -$2.23);
  • Ionis Pharmaceuticals (IONS -$0.80 after Wednesday’s +$0.74);
  • Editas Medicine (EDIT -$0.55 after Wednesday’s -$0.13, Tuesday’s +$2.15 after Monday’s +$0.05);
  • Fate Therapeutics (FATE -$0.33 after Wednesday’s +$5.83, Tuesday’s +$3.90 and Monday’s -$2.99);
  • Brainstorm Cell Therapeutics (BCLI -$0.31 after Wednesday’s -$0.05);
  • Cellectis SA (CLLS -$0.21);
  • Homology medicine (FIXX -$0.19);
  • Sage Therapeutics (SAGE -$0.17 after Wednesday’s +$3.73, Tuesday’s -$2.74 and Monday’s -$1.93);
  • Global Blood Therapeutics (GBT -$0.14);

Closing: 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19:

  • Pfizer CEO Albert Bourla said PFE can deliver 10% more vaccine doses to the U.S. by the end of May than previously expected.

COVID Data Tracker <Million>:

  • Thursday 31,2 M cases,
  • Thursday’s death rate totaled 561,356 <Johns Hopkins University>
  • Thursday vaccinations: 198 M

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +1.22% and XBI closed up +0.88%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.42 points or -2.47% at 16.57

Upside volume: low

  • Thursday: 0 out of the 18-upside had higher than the 3-month average volume;

Downside volume: low

  • Thursday: 1 out of the 16-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Thursday’s percentage (%) of the 18-upside were +0.33% (BLFS) to +13.68% (BSTG) while the 16-downside ranges from -0.22% (SAGE) to -8.81% (BCLI);

 

April, the beginning of Q2/21:

Thursday closed positive with 18 advancers, 16 decliners and 1 acquired

 

The BOTTOM LINE: Enjoy it, the cell and gene therapy sector was up for the third (3rd) session in a row – an achievement in this month.

But I am NOT buying into sustainability … I have been wrong yet, I have been righter, more often as mini-rotations have made the sector rally challenging, despite the 3-session uptrend.

Q1/21 earnings are being announced, AxoGen (AXGN) on Wednesday, 5/5 and Athersys (ATHX) on Thursday, 5/6.

Sector momentum remains “sketchy” and these depressed pricing guarantees more uncertainty and risks but, some rebounds.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

Don’t get complacent …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.